Dexton

Dexamethasone Na phosphate

Anti-inflammatory, anti-allergy, & for other conditions requiring corticosteroid therapy. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment; seasonal or perennial allergic rhinitis, bronchial asthma, contact or atopic dermatitis, serum sickness, drug hypersensitivity reactions; acute non-infectious laryngeal edema, urticarial transfusion reactions. During exacerbation or as maintenance therapy in selected cases of SLE or acute rheumatic carditis. Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (SJS); exfoliative dermatitis & erythroderma, mycosis fungoides; severe psoriasis; severe seborrheic dermatitis. To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or due to SLE. Primary, secondary, or acute adrenocortical insufficiency; pre-op & in the event of serious trauma or illness, in adrenal insufficiency or when adrenocortical reserve is doubtful; septic shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected; congenital adrenal hyperplasia; non-suppurative thyroiditis; hypercalcemia associated w/ cancer. Ulcerative colitis or regional enteritis. Immune & secondary thrombocytopenia in adults; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia). Acute exacerbations of multiple sclerosis; cerebral edema associated w/ primary or metastatic brain tumor craniotomy. Severe acute & chronic allergic & inflammatory processes involving eye & its adnexa eg, allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, herpes zoster ophthalmicus, iritis & iridocyclitis, chorioretinitis, anterior segment inflammation, diffuse posterior uveitis & choroiditis, optic neuritis, sympathetic ophthalmia; temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Symptomatic sarcoidosis; Loeffler syndrome not manageable by other means; berylliosis; fulminating or disseminated pulmonary TB when used concurrently w/ antituberculous chemotherapy; aspiration pneumonitis, idiopathic eosinophilic pneumonias. Dermatomyositis, polymyositis & SLE. Keloids; localized hypertrophic, infiltrated inflammatory lesions of lichen planus, psoriatic plaques, granuloma annulare & lichen simplex chronicus (neurodermatitis); discoid lupus erythematosus; necrobiosis lipoidica diabeticorum; alopecia areata; cystic tumors of aponeurosis or tendon (ganglia). Adjunct for short-term administration in psoriatic & acute gouty arthritis, RA, juvenile RA, ankylosing spondylitis, acute & subacute bursitis, acute nonspecific tenosynovitis, post-traumatic OA, synovitis of OA, epicondylitis. Palliative management of leukemias & lymphomas in adults & acute leukemia of childhood.

IM/IV Initially 0.5-9 mg daily. Acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders In combination w/ oral therapy: 4-8 mg IM on 1st day followed by tab. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected 1-6 mg/kg as single IV inj or 20 mg IV followed by 3 mg/kg every 24 hr by continuous IV infusion, or 40 mg IV every 2-6 hr while shock persists. Nervous system disorders Initially 10 mg IV followed by 4 mg IM every 6 hr. May reduce dose after 2-4 days, then gradually tapered over 5-7 day period. Patient w/ recurrent or inoperable brain tumors Maintenance: 2 mg bid or tid. IA or soft tissue inj/Intralesional inj Inflammatory disorder of musculoskeletal system & skin disorder Usual dose: 0.2-6 mg. 0.4-1 mg in tendon sheaths, 0.8-1 mg in small joints, 1-2 mg in ganglia, 2-3 mg in bursae, 2-4 mg in large joints, 2-6 mg for soft tissue infiltration. Frequency: Once every 3-5 days to once every 2-3 wk. Ped Usual dose: 0.2-0.4 mg/kg daily.

Hypersensitivity. Disseminated or systemic fungal infections; ocular herpes simplex, severe psychoneurosis, TB.

Peptic or duodenal ulcer, DM, viral infections. Renal & hepatic impairment. May cause irreversible growth retardation in infancy, childhood & adolescence. Carefully monitor growth & development in infants & childn on prolonged therapy. Elderly (use smallest possible dose).

Fluid & electrolyte retention, increased susceptibility to infection; growth retardation; Cushingoid states; amenorrhea; hyperhidrosis, mental disturbances; intracranial HTN; acute pancreatitis; aseptic osteonecrosis.

Concomitant use w/ barbiturates, phenytoin, rifampicin.

Corticosteroid Hormones

H02AB02 - dexamethasone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.

S